GlassScriptPhysician profile
Richard Kalman
NPI 1184891020
$12,957.22
in general payments reported to CMS, 2019-2025
12 companies · $5,006 in 2025
The $5,006 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $22.32 · 2021: $26.84 · 2022: $1,888 · 2023: $27.73 · 2024: $5,874 · 2025: $5,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Food and Beverage: $627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,280.00 |
| Food and Beverage | $627.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $10,776.80 | 2020-2025 | Livdelzi |
| Genentech USA, INC. | $1,852.00 | 2022 | |
| Eisai INC. | $189.87 | 2019-2024 | |
| Abbvie INC. | $50.08 | 2022-2023 | |
| Alkermes, INC. | $33.66 | 2025 | Vivitrol |
| Boston Scientific Corporation | $26.84 | 2021 | |
| Abbott Laboratories | $14.39 | 2020 | |
| Medtronic, INC. | $13.58 | 2023 | Interstim |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Kalman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.